Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2020 Aug 3;86(3):325–337. doi: 10.1007/s00280-020-04114-z

Fig. 5.

Fig. 5

Clinical trial simulation for time course of overall survival based on in vitro data of quizartinib once-daily and once every 2 days quizartinib dosing regimen simultaneously administered with cytarabine as described in [54]. Median simulated OS (95% confidence interval) for the once daily are 12.6 (11.5, 14.4) months and the once every 2 days regimen are 16.7 (16.0, 18.7) months